Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Grande Portage Resources (V.GPG) Initiates Sensor-Based Ore Sorting Testwork (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Akero Therapeutics Inc AKRO

Healthcare Biotechnology
Akero Therapeutics, Inc. is a clinical-stage company. The Company is developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH), a disease without any approved therapies. Efruxifermin (EFX), is its lead product candidate for MASH, which is being evaluated in the ongoing... see more

Recent & Breaking News (NDAQ:AKRO)

Akero Therapeutics Announces Proposed Public Offering of Common Stock

PR Newswire July 6, 2020

Akero Announces Strongly Positive Histological Data Across All Efruxifermin Dose Groups in 16-Week Phase 2a BALANCED Study in NASH Patients

PR Newswire June 30, 2020

Akero Therapeutics to Announce New Data from NASH Phase 2a BALANCED Study of AKR-001

PR Newswire June 29, 2020

Akero Therapeutics Doses First Patient in Expansion of Phase 2a Trial in NASH

PR Newswire June 17, 2020

Akero Therapeutics Appoints Tom Heyman to its Board of Directors

PR Newswire June 10, 2020

Akero Therapeutics To Present At The Jefferies Virtual Healthcare Conference

PR Newswire May 26, 2020

Akero Therapeutics Reports First Quarter 2020 Financial Results

PR Newswire May 13, 2020

All AKR-001 Dose Groups Met Week 12 Efficacy Endpoints in NASH Phase 2a BALANCED Study

PR Newswire March 31, 2020

Akero Therapeutics to Announce Results for Week 12 Efficacy Endpoints from NASH Phase 2a BALANCED Study of AKR-001

PR Newswire March 30, 2020

Akero Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results

PR Newswire March 16, 2020

Akero Therapeutics Expands Phase 2a Trial in NASH to Include Cohort of Cirrhotic Patients

PR Newswire January 13, 2020

Akero Therapeutics To Present At The 2020 J.P. Morgan Healthcare Conference

PR Newswire January 8, 2020

Akero Therapeutics Completes Enrollment in Phase 2a Study in NASH

PR Newswire December 16, 2019

It's Been A Particularly Exciting Year For Biotech Stocks Across The Board

Livemoney November 26, 2019

Akero Therapeutics to Present at the Jefferies 2019 London Healthcare Conference

PR Newswire November 13, 2019

Akero Therapeutics Reports Recent Highlights and Third Quarter 2019 Financial Results

PR Newswire November 12, 2019

InSphero Wins Sino-European Innovation Award for Breakthrough NASH Discovery and Safety Testing Platform

PR Newswire November 4, 2019

Akero Therapeutics To Present At The Morgan Stanley 17th Annual Global Healthcare Conference

PR Newswire September 4, 2019

Arbutus Biopharma Appoints Andrew Cheng, M.D., Ph.D., to its Board of Directors

GlobeNewswire August 20, 2019